stockrowAlaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024.
- Revenue
- +200.0%
- EPS
- +34.9%
- Free cash flow
- +57.2%
Quarter to June 2026, against a year earlier
Follow TCRT
Alert me
Alaunos Therapeutics, Inc. (TCRT) EV/Sales
As of 6 November 2026, Alaunos Therapeutics, Inc. (TCRT) trades at a EV/Sales of 1,408×. Over the past ten years it has ranged from 4.3× (December 2023) to 2,385× (July 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,455× | (8.17%) |
| FY2024 | 1,584× | 15,462.42% |
| FY2023 | 10.2× | (66.17%) |
| FY2022 | 30.1× | (38.13%) |
| FY2021 | 48.6× | 16.16% |
| FY2018 | 41.9× | (50.22%) |
| FY2017 | 84.1× | (8.77%) |
| FY2016 | 92.2× | (55.72%) |
| FY2015 | 208× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1,455× | (0.21%) |
| Mar 2025 | 1,458× | (7.98%) |
| Dec 2024 | 1,584× | (32.33%) |
| Jun 2024 | 2,341× | 1.19% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| SNGX Soligenix Inc. compare | −4.1× |
| LTRN Lantern Pharma Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.0× |
| TPST Tempest Therapeutics, Inc. compare | 22.4× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 25.3× |
| TCRT Alaunos Therapeutics, Inc. | 1,408× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)